Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) EBITDA: 2018-2021

Historic EBITDA for Black Diamond Therapeutics (BDTX) over the last 4 years, with Dec 2021 value amounting to -$126.6 million.

  • Black Diamond Therapeutics' EBITDA fell 15.45% to -$26.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$115.0 million, marking a year-over-year decrease of 74.40%. This contributed to the annual value of -$126.6 million for FY2021, which is 90.01% down from last year.
  • Per Black Diamond Therapeutics' latest filing, its EBITDA stood at -$126.6 million for FY2021, which was down 90.01% from -$66.6 million recorded in FY2020.
  • In the past 5 years, Black Diamond Therapeutics' EBITDA ranged from a high of -$8.9 million in FY2018 and a low of -$126.6 million during FY2021.
  • Over the past 3 years, Black Diamond Therapeutics' median EBITDA value was -$66.6 million (recorded in 2020), while the average stood at -$76.2 million.
  • Data for Black Diamond Therapeutics' EBITDA shows a maximum YoY plummeted of 295.98% (in 2019) over the last 5 years.
  • Yearly analysis of 4 years shows Black Diamond Therapeutics' EBITDA stood at -$8.9 million in 2018, then slumped by 295.98% to -$35.3 million in 2019, then tumbled by 89.01% to -$66.6 million in 2020, then crashed by 90.01% to -$126.6 million in 2021.